10-K: Ginkgo Bioworks Reports FY24 Results, Focuses on Cell Engineering and Biosecurity Growth

Ginkgo Bioworks' FY24 results highlight a strategic shift towards cell engineering and biosecurity, amidst restructuring and operational changes.

Summary

• Ginkgo Bioworks' FY24 results show a net loss of $547 million, with a strategic focus on cell engineering and biosecurity.
• The company is undergoing restructuring actions commenced in 2024 to reduce operational expenditures.
• Cell engineering revenue increased to $174 million, driven by non-cash revenue from a terminated contract and growth in programs with large enterprise customers.
• Biosecurity revenue decreased to $53.1 million due to the end of COVID-19 testing services, but the company is focusing on global surveillance programs and analytic services.
• The company believes its cash and investments are sufficient to fund operations until profitability.
• Ginkgo is investing in AI and machine learning to improve its cell engineering platform.
• The company is expanding its biosecurity platform with Canopy and Horizon offerings.
• Ginkgo is subject to various regulations, including FDA, DEA, and EPA, and faces risks related to intellectual property, competition, and customer relationships.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's growth in cell engineering and a focus on biosecurity, the significant net loss and restructuring efforts indicate challenges. The company's future outlook is uncertain, balancing potential growth with financial constraints.

Positives

• Cell engineering revenue increased to $174 million.
• Ginkgo is focusing on global surveillance programs and analytic services in biosecurity.
• The company is investing in AI and machine learning to improve its cell engineering platform.
• The company has $561.6 million in cash and cash equivalents as of December 31, 2024.
• The company is expanding its biosecurity platform with Canopy and Horizon offerings.

Negatives

• Ginkgo Bioworks reported a net loss of $547 million for FY24.
• Biosecurity revenue decreased to $53.1 million.
• The company is undergoing restructuring to reduce operational expenditures.

Risks

• The company may need substantial additional capital in the future.
• The company faces intense competition and competitive pressures.
• The company is subject to litigation, including securities or shareholder litigation.
• The company may be unable to complete future strategic acquisitions or successfully integrate strategic acquisitions.
• The company's programs may not achieve milestones or earn royalties.
• The company must continue to secure and maintain sufficient and stable supplies of laboratory reagents, consumables, equipment, and laboratory services.
• The company uses biological, hazardous, flammable and/or regulated materials that require considerable training, expertise and expense for handling, storage and disposal and may result in claims against us.
• Third parties may use our engineered cells, materials, and organisms and accompanying production processes in ways that could damage our reputation.
• The company's investments in and use of AI may result in reputational harm, liabilities, or other adverse consequences to our business operations.
• The company's recent restructuring actions in connection with our plans to reduce operational expenditures may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.
• The company is dependent on our customers willingness and ability to develop, produce and manufacture products using the engineered cells, other biological assets and/or biomanufacturing processes that we develop and on the success of our customers development, production, and manufacturing efforts.
• The company's revenue is concentrated in a limited number of customers, some of which are related parties, and our revenue, results of operations, cash flows and reputation may suffer upon the loss of a significant customer.
• The company may be subject to tort liability if the COVID-19 tests we utilized in our testing programs provided inaccurate results.
• The company may be unable to complete future strategic acquisitions or successfully integrate strategic acquisitions which could adversely affect our business and financial condition.
• The company's programs may not achieve milestones, earn royalties or complete other anticipated key events on the expected timelines or at all, which could have an adverse impact on our business and could cause the price of our common stock to decline.
• The company must continue to secure and maintain sufficient and stable supplies of laboratory reagents, consumables, equipment, and laboratory services.
• The company uses biological, hazardous, flammable and/or regulated materials that require considerable training, expertise and expense for handling, storage and disposal and may result in claims against us.
• Third parties may use our engineered cells, materials, and organisms and accompanying production processes in ways that could damage our reputation.
• International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.
• The company's investments in and use of AI may result in reputational harm, liabilities, or other adverse consequences to our business operations.
• The company's recent restructuring actions in connection with our plans to reduce operational expenditures may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.
• If we cannot maintain and expand current customer partnerships and enter into new customer partnerships, our cell engineering business could be adversely affected.
• We have exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration.
• We leverage our own resources and partner with strategic and financial investors in order to help early stage companies and innovators secure funding and benefit from our platform, which exposes us to a number of risks.
• We may be unable to complete future strategic acquisitions or successfully integrate strategic acquisitions which could adversely affect our business and financial condition.
• Our programs may not achieve milestones, earn royalties or complete other anticipated key events on the expected timelines or at all, which could have an adverse impact on our business and could cause the price of our common stock to decline.
• We must continue to secure and maintain sufficient and stable supplies of laboratory reagents, consumables, equipment, and laboratory services.
• We use biological, hazardous, flammable and/or regulated materials that require considerable training, expertise and expense for handling, storage and disposal and may result in claims against us.
• Third parties may use our engineered cells, materials, and organisms and accompanying production processes in ways that could damage our reputation.
• International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.
• Our investments in and use of AI may result in reputational harm, liabilities, or other adverse consequences to our business operations.
• Our recent restructuring actions in connection with our plans to reduce operational expenditures may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.
• If we cannot maintain and expand current customer partnerships and enter into new customer partnerships, our cell engineering business could be adversely affected.
• We are dependent on our customers willingness and ability to develop, produce and manufacture products using the engineered cells, other biological assets and/or biomanufacturing processes that we develop and on the success of our customers development, production, and manufacturing efforts.
• Our revenue is concentrated in a limited number of customers, some of which are related parties, and our revenue, results of operations, cash flows and reputation may suffer upon the loss of a significant customer.
• We may be subject to tort liability if the COVID-19 tests we utilized in our testing programs provided inaccurate results.
• Rapidly changing technology and emerging competition in the synthetic biology industry could make the platform, programs, and products we and our customers are developing obsolete or non-competitive unless we continue to develop our platform and pursue new market opportunities.
• Ethical, legal and social concerns about GMOs and Genetically Modified Materials and their resulting products could limit or prevent the use of products or processes using our technologies, limit public acceptance of such products or processes and limit our revenues.
• If we are unable to obtain, maintain and defend patents protecting our intellectual property, our competitive position could be harmed. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position will be harmed. We may become involved in lawsuits or other enforcement proceedings to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and potentially unsuccessful.
• We rely on our customers, joint venturers, equity investees and other third parties to deliver timely and accurate information in order to accurately report our financial results in the time frame and manner required by law.
• We had in the past identified a material weakness in our internal controls over financial reporting, and we may identify additional material weaknesses in the future. A failure to maintain an effective system of internal control over financial reporting may result in a failure to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.
• Failure to comply with federal, state, local and international laws and regulations could expose us to significant liabilities or penalties and adversely affect our business, our financial condition and results of operations and we may incur significant costs complying with such laws and regulations
• We and our laboratory partners are subject to a variety of laboratory testing standards, compliance with which is an expensive and time-consuming process, and any failure to comply could result in substantial penalties and disruptions to our business.
• Significant disruptions to our and our service providers information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.

Future Outlook

The company expects operating expenses to either remain consistent or decline in 2025 compared to 2024 and believes that its cash and cash equivalents, short-term investments, and interest earnings will be sufficient to meet its projected operating requirements until it reaches profitability.

Management Comments

• Our mission is to make biology easier to engineer.
• Every choice we've made with respect to our business model, our platform, our people, and our culture is grounded in whether it will advance our mission.

Industry Context

Ginkgo operates in the rapidly evolving synthetic biology industry, facing competition from internal R&D departments, verticalized cell engineering platforms, CROs, life science tools companies, and potential new entrants.

Comparison to Industry Standards

• Ginkgo faces competition from companies like AbCellera (antibody discovery), Codexis (enzymes), Senti Bio (cell therapy), and WuXi Biologics (therapeutics).
• The company also competes with CROs like Evotec, WuXi Biologics, and Charles River Laboratories, as well as automation companies like HighRes Biosolutions, Automata, and Thermo Fisher Scientific.

Legal Proceedings

• The company has been and may in the future be a target for securities and shareholder lawsuits.

Related Party Transactions

• The company has derived, and may continue to derive, a significant portion of our revenue from a limited number of large customers, some of which are related parties.

Stakeholder Impact

• The company's performance and restructuring actions could impact shareholders, employees, customers, suppliers, and creditors.

Next Steps

• Continue to develop our platform and pursue new market opportunities.
• Continue to evaluate potential opportunities for international expansion.
• Continue to evaluate our space needs and offer any excess space for subleasing.

Key Dates